Pasithea Therapeutics Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
42.6%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.76next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Interim Phase 1/1b NF1 Clinical Trial Data Update | 15 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Cash Equivalents Quarterly50.4MTarget: Sufficient to fund operations into at least H1 2028
Quarterly Net Loss Quarterly-2.9MTarget: Narrowing loss through disciplined cost management
PAS-004 Phase 1/1b NF1 Trial Enrollment Quarterly18.0Target: Complete Part A dose escalation and select Recommended Phase 2 Dose (RP2D) for Part B
Watch Items
- Nasdaq Minimum Bid Price ComplianceTrigger: Closing bid price below $1.00 for 30 consecutive business days (Deficiency notice received Feb 20, 2026)Action: Regain compliance by closing at or above $1.00 for at least 10 consecutive business days before August 19, 2026, or implement a reverse stock split.
- PAS-004 Phase 1/1b NF1 Interim Data ReleaseTrigger: Data readout scheduled for Q4 2026Action: Evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy (including cutaneous and plexiform neurofibroma measurements) to de-risk the asset.
- R&D Expense EscalationTrigger: R&D expenses rising significantly (up 70.1% YoY to $2.94M in Q1 2026)Action: Monitor cash burn rate and adjust operational runway projections to ensure capital lasts into 2028.
Research as of 20 Jun 2026